NCT00270465 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Calmy A, Pascual F, Ford N
HIV drug resistance. N Engl J Med. 2004 Jun 24;350(26):2720-1.
Clough LA, D'Agata E, Raffanti S, Haas DW
Factors that predict incomplete virological response to protease inhibitor-based antiretroviral therapy. Clin Infect Dis. 1999 Jul;29(1):75-81; discussion 82-4.
Lucas GM, Chaisson RE, Moore RD
Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999 Jul 20;131(2):81-7.

VRC101: A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-Boost HIV-1 Vaccination Schedule of a 6-Plasmid Multiclade HIV-1 DNA Vaccine, VRC-HIVDNA016-00-VP, Followed by a Recombinant Multiclade Adenoviral Vector HIV Vaccine

Details for clinical trial NCT00270465

Clinical trial NCT00270465 - References